文献速递乳房整形与再造创面修复

新辅助与辅助化疗对乳房切除术后胸肌前组织扩张器重建结局的影响

Association of Neoadjuvant Versus Adjuvant Chemotherapy on Pre-Pectoral Tissue Expander Based Reconstruction Outcomes Following Mastectomy.
PubMed 文献 · Plast Reconstr Surg · 2026-10-14

该单中心回顾性研究纳入2018年1月至2022年9月间295例二期即刻胸肌前组织扩张器乳房重建患者,按新辅助化疗、辅助化疗或无化疗分层。新辅助化疗组在组织扩张器置入后的主要并发症发生率低于辅助化疗组和无化疗组(14.1% vs 41.8% vs 28.5%,p=0.0012),辅助化疗与更高的主要并发症风险相关。

要点

  • 辅助化疗与胸肌前组织扩张器置入后更高的主要并发症风险相关。
  • 新辅助化疗并非并发症的预测因素,与无化疗相比无显著差异。
  • 围手术期白细胞减少与置入后主要感染率降低但血肿率升高相关。

核心结论

  • 在本队列中,辅助化疗与胸肌前组织扩张器置入后更高的主要并发症风险相关。
  • 新辅助化疗和围手术期白细胞减少与无化疗相比并非并发症的预测因素。

研究设计与样本

  • 单中心回顾性综述,评估2018年1月至2022年9月间所有二期即刻胸肌前乳房重建患者的 surgical outcomes。
  • 共分析295例患者,按治疗类型(新辅助化疗、辅助化疗或无化疗)分层,并区分是否存在白细胞减少。
  • 组间并发症率采用单变量比较,主要并发症采用多变量混合效应逻辑回归分析。

主要发现

  • 新辅助化疗组组织扩张器置入后主要并发症发生率为14.1%,辅助化疗组为41.8%,无化疗组为28.5%(p=0.0012)。
  • 各组在单个并发症或假体置换后结局方面无显著差异。
  • 围手术期白细胞减少患者组织扩张器置入后主要感染率更低但血肿率更高(p<0.05)。
  • 围手术期白细胞减少患者假体置换后取出率更低但再手术率和皮肤坏死率更高(p<0.05)。

临床怎么用

  • 对于拟行胸肌前组织扩张器重建的患者,辅助化疗可能提示更高的主要并发症风险,需加强围手术期监测。
  • 新辅助化疗本身不应被视为胸肌前组织扩张器重建的禁忌,但围手术期白细胞减少需关注血肿和皮肤坏死风险。

局限性

  • 单中心回顾性设计可能限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prepectoral implant-based reconstruction has reemerged as a preferred technique for breast reconstruction after mastectomy, but introduces risks of prothesis infection. With increasing reliance on neoadjuvant chemotherapy (NACT), which can modulate the immune system and induce leukopenia, it is unclear how NACT impacts surgical outcomes in prepectoral reconstruction patients. This retrospective review aims to investigate the impact of NACT and leukopenia on complication rates in patients undergoing immediate pre-pectoral TE-based breast reconstruction compared to adjuvant chemotherapy or no chemotherapy. METHODS: A single-center retrospective review evaluated surgical outcomes in all two-stage immediate prepectoral breast reconstruction patients between January 2018 and September 2022. Patients were stratified by treatment type (NACT, ACT, or none) and the presence of leukopenia was delineated. Complication rates between groups were analyzed with univariate comparisons and a multivariate mixed effects logistic regression was run for major complications. RESULTS: Of the 295 patients analyzed, those with NACT experienced fewer major complications compared to the ACT or no chemotherapy cohorts (14.1% vs 41.8% vs 28.5%, p = 0.0012) following TE placement. There were no significant differences in individual complications or outcomes following implant exchange. Patients with perioperative leukopenia experienced lower major infections rates, but higher hematoma rates following TE placement (p<0.05). Following implant exchange, they experienced lower explantation rates but higher reoperation and skin necrosis rates (p<0.05). CONCLUSION: This study demonstrates that ACT is associated with higher risks of major complications after prepectoral tissue expander placement in our cohort, but that NACT and perioperative leukopenia were not predictors of complications compared to no chemotherapy.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Dang JM, Gupta N, Alnaseri T, et al. Association of Neoadjuvant Versus Adjuvant Chemotherapy on Pre-Pectoral Tissue Expander Based Reconstruction Outcomes Following Mastectomy. Plast Reconstr Surg. 2026. PMID: 42873130. doi:10.1097/PRS.0000000000013520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。